Polymyxin B
POLY-RX
“Poly-mixin’ Bee”
Name from Bacillus polymyxa; poly = many; myxa = mucus
What it isCationic peptide disrupting the Gram-negative outer membrane; topical combinations and systemic multidrug-resistant infection.
Why this oneUnlike colistin, systemic polymyxin B is administered as the active drug rather than a prodrug, making exposure more predictable.
What limits itSystemic use is nephrotoxic and neurotoxic. Topically it is a common cause of allergic contact dermatitis.
FDA-approved for
- gram-negative infections (topical, ophthalmic, otic)
FDA label
Read the full label on DailyMed ↗
BOXED WARNING IM/intrathecal use restricted to hospitalized, physician-supervised patients; nephrotoxicity (albuminuria, azotemia — discontinue for falling urine output/rising BUN) and neurotoxicity incl. respiratory paralysis from neuromuscular blockade (esp. after anesthesia/muscle relaxants); avoid concurrent nephro-/neurotoxic drugs; reduce dose in renal impairment; safety in pregnancy not established.
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Susceptible P. aeruginosa and other gram-negative infections (UTI, bloodstream) | Adults and children (normal renal function) | IV 15,000-25,000 units/kg/day continuous drip (may divide q12h) | 15,000-25,000 units/kg/day | 25,000 units/kg/day |
| Susceptible gram-negative infections | Infants (normal renal function) | IV up to 40,000 units/kg/day | 40,000 units/kg/day | |
| Susceptible gram-negative infections (IM — not routine; severe injection-site pain) | Adults and children | IM 25,000-30,000 units/kg/day divided q4-6h | ||
| P. aeruginosa meningitis (intrathecal only) | Adults and children >2 yr | 50,000 units intrathecally QD x3-4 days | 50,000 units every other day | Continue >=2 wk after negative CSF cultures |
| P. aeruginosa meningitis (intrathecal only) | Children <2 yr | 20,000 units intrathecally QD x3-4 days (or 25,000 units QOD) | 25,000 units every other day | Continue >=2 wk after negative CSF cultures |
| P. aeruginosa eye infections (topical ophthalmic) | Adults | 1-3 drops of 10,000-25,000 units/mL solution q1h, extending interval per response | Subconjunctival up to 100,000 units/day; total systemic+ophthalmic <=25,000 units/kg/day |
Renal Reduce dose downward from 15,000 units/kg/day in renal impairment; monitor renal function closely (boxed warning)
Hepatic Undefined
Doses expressed in polymyxin B units, not mg
Instructions
- IV: dissolve 500,000 units in 300-500 mL D5W for continuous drip
- Meningeal infections: administer only by the intrathecal route
- Determine baseline renal function; monitor renal function and drug levels frequently during parenteral therapy
- Avoid concurrent curariform muscle relaxants and other neurotoxic drugs (risk of respiratory depression)
- Refrigerate parenteral solutions; discard unused portions after 72 h
Available strengths
- inj 500000 units
Contraindications
- Prior history of hypersensitivity reactions to polymyxins
Cautions
- Nephrotoxicity — discontinue for diminishing urine output or rising BUN (boxed)
- Neurotoxicity: irritability, ataxia, perioral paresthesia, blurred vision; can cause respiratory paralysis via neuromuscular blockade, esp. after anesthesia/muscle relaxants (boxed)
- Avoid concurrent/sequential nephro- or neurotoxic drugs (aminoglycosides, bacitracin, colistin, etc.) (boxed)
- Electrolyte/acid-base abnormalities (Pseudo-Bartter syndrome: hypokalemia, metabolic alkalosis) — consider electrolyte monitoring
- C. difficile-associated diarrhea
- Superinfection with nonsusceptible organisms incl. fungi
Adverse reactions
- Nephrotoxic: albuminuria, cylinduria, azotemia, rising drug levels
- Neurotoxic: facial flushing, dizziness progressing to ataxia, drowsiness, peripheral (circumoral/stocking-glove) paresthesias, apnea
- Meningeal irritation with intrathecal use (fever, headache, stiff neck, CSF pleocytosis)
- Drug fever, urticarial rash; severe pain at IM sites; thrombophlebitis at IV sites
Pregnancy Safety in human pregnancy not established (boxed warning).
Lactation Undefined
Cost
Polymyxin B (POLY-RX)
| Strength | #/mo | generic $/unit | CostPlus | |
|---|---|---|---|---|
| 500000 units | inj | per unit | not offered |
NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Polymyxin B is administered under clinical supervision and dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.
Generic entry1983
⚠ BOXED WARNINGS
- Nephrotoxicity and neurotoxicity
- Neuromuscular blockade
Classes and tags
Clinical profile
Legacy pregnancy categoryC
Defining liabilityAllergy, gastrointestinal effects and agent-specific renal, hepatic, hematologic or interaction risks.
Open Polymyxin B in the interactive console ↗
Memory aids: interaction avatars
